Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

DNB Markets - Nexam Chemical: Q3 is history, opportunities ahead

Q3 sales missed our forecast by 13%, driven mainly by vacation effects but also the general raw-material shortage globally, which may have pushed some sales into Q4e. However, this has not changed our view of Nexam Chemical, and we still believe the 2022 sales target of SEK275m–325m is within reach with its current platforms. Following the Q3 results and a change of analyst, we have lowered our estimates slightly but reiterate our fair value of SEK15–20. We estimate a strong end to 2021 and consider the company well-positioned to continue executing on its profitable growth journey. Additional

#21-349 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

#21-348 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

RaySearch and Mevion to develop next-generation treatment planning techniques for FLASH proton radiotherapy treatment

RaySearch Laboratories AB (publ) and Mevion Medical Systems, two companies that are leading the field of proton therapy, announce a collaboration to develop advanced treatment planning techniques for FLASH* delivery with the MEVION S250i Proton Therapy System.The collaboration will explore FLASH intensity modulated proton therapy (IMPT) delivery using a technique that supports the delivery of large-volume clinical FLASH fields through the combination of smaller fields, each delivered at FLASH dose rates which complements Mevion’s advanced HYPERSCAN delivery system.  Townsend Zwart, Vice

Stabilisation Notice

Goldman Sachs Bank Europe SE ("Goldman Sachs") has, in its capacity as Joint Global Coordinator and Stabilization Manager, notified Truecaller AB (publ) ("Truecaller" or the "Company") that stabilization measures have been undertaken in the Company's class B shares traded on Nasdaq Stockholm.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER

Profit warning: Apetit revises its estimate of operating profit for 2021 and provides preliminary information for the period January - September 2021

Apetit Plc, Inside information, 22 October 2021 at 17:35 p.m.Profit warning: Apetit revises its estimate of operating profit for 2021 and provides preliminary information for the period January - September 2021 Apetit Plc revises its estimate of operating profit for 2021. The company estimates that the operating profit from continuing operations will be below year 2020 level (EUR 3.9 million in 2020). Record-high freight costs and unfavorable sales commitments in relation to the grain harvest quality will weaken Grain Trade's profit outlook for the last quarter of the year. The profit

Exercise of employee share options in Atea ASA ("the Company")

Employees in the Atea Group have exercised 12,633 options.With reference to the share repurchase program announced on 17 September 2021, Atea have used 12,633 of its own shares to fulfill the company's obligations under its employee stock option agreements. Following this transaction, the company holds 897,567 of its own shares. No primary insiders have exercised options. For further information, please contact:Steinar Sønsteby, CEO Atea ASA, mobile (+47) 930 55 655Robert Giori, CFO Atea ASA, mobile (+47) 934 09 188

The coffee specialist Bean 14 chooses DUG

From its base on the Channel Island of Guernsey, Bean 14 spreads knowledge about – and equipment to make – the perfect coffee to customers, mainly on other Channel Islands and in the UK. Bean 14 has now chosen to include Veg of Lund’s plant-based drink DUG in its offer.Bean 14 was started by Chris Bader in 2006 and the company has since established itself as a specialist in the coffee and café industry. With its own roastery and equipment from leading machine manufacturers, Bean 14’s online store offers high-quality coffee and related products to cafés and other professional customers

Tobii and Pimax Announce New Partnership to Bring Eye Tracking to Consumer Virtual Reality Headsets

Tobii, the world leader in eye tracking and pioneer in attention computing, announced today its partnership with Pimax Innovation, a direct-to-consumer technology company specializing in advanced virtual reality (VR) hardware products.  The partnership will make eye tracking a standard feature and implement dynamic foveated rendering in the upcoming generation of Pimax's high-end headsets. With Tobii eye tracking, users can have an embodied presence, stay comfortably in different worlds for long hours, and immerse themselves in the most natural way. This brings the full potential of the

Notice to attend the Annual General Meeting in Quickbit eu AB (publ)

Shareholders of Quickbit eu AB (publ) are hereby invited to the Annual General Meeting on 24 November 2021.N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. In order to prevent the spread of the coronavirus infection (COVID-19), the Board of Directors has decided that the Annual General Meeting shall be held without physical presence of shareholders, proxies and/or external parties and that the shareholders shall have the opportunity to vote by post prior to the

Completion of Golden Eagle Acquisition

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.  FOR IMMEDIATE RELEASE. 22 October 2021 EnQuest PLC Completion of the acquisition of the Golden Eagle Area Development EnQuest PLC ("EnQuest", or the "Company") is pleased to announce that it has completed the acquisition ("Completion") of a 26.69% non-operated

ASETEK PRESENTS THIRD QUARTER 2021 RESULTS ON THURSDAY, 28 OCTOBER

Asetek will release its financial results for the third quarter of 2021 on Thursday, 28 October at 7:00 AM CEST. CEO André Sloth Eriksen and CFO Peter Dam Madsen will present the Company's results at 8:00 AM CEST and invites investors, analysts and media to join the presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed via live webcast or conference call. Webcast - audio and slide presentation:Please join the results webcast via the following link: https://streams.eventcdn.net/asetek/2021q3 Conference call - audio only:Please dial

Cantargia reports treatment of first patient in CESTAFOUR clinical trial

Cantargia AB today announced that the first patient has started treatment with nadunolimab (CAN04) and chemotherapy in the phase I/II clinical trial CESTAFOUR. This trial evaluates CAN04 in combination with standard of care chemotherapy in three different forms of cancer: biliary tract cancer (BTC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) and is planned to include up to a total of 165 patients.The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN04 is Cantargia’s lead program and is investigated in multiple clinical trials. Approval was recently

RNB Retail and Brands AB meets the listing requirements for Nasdaq First North Growth Market and publishes company description of Coala-Life AB

RNB Retail and Brands AB ("RNB" or "the Company") announces that Nasdaq Stockholm AB has today announced that the Company meets the listing requirements for Nasdaq First North Growth Market. RNB today also publishes the company description prepared in connection with the transaction that RNB published in a press release on 27 September 2021, whereby RNB intends to acquire Coala-Life AB ("Coala Life") through a non-cash issue and further carry out a change of marketplace from Nasdaq Stockholm. to Nasdaq First North Growth Market. Provided that the Extraordinary General Meeting of RNB

DexTech Medical AB Interim report July 1 2021 - September 30, 2021

Summary of the First Quarter (2021-07-01 – 2021-09-30) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -0,9 (-1,5) • Earnings per share* SEK -0,06 (-0.10) • Cash and cash equivalents at the end of the period amounted to MSEK 3,0 (5,5) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 14,920,478. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year. CEO's comment There are significant similarities

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B635TG28 Issuer Name ENQUEST PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Cobas Asset Management, SGIIC, S.A. City of registered office (if applicable) Madrid Country of registered office (if applicable) Spain 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation,

“Quarantine-free” Holiday in Thailand from 1 November 2021

Thailand reopen to fully vaccinated foreign visitors, including returning Thais and foreign residents, from the approved countries to enter the Kingdom by air with no quarantine requirements from 1 November, 2021. Key Points · Fully vaccinated travelers against COVID-19 from 46 nations includingNordic and Baltic to visit Thailand · Travelers must take 2 RT-PCR COVID tests (72 hrs before flight and onarrival day at the hotel), And Antigen self-test kit on day 6-7. · Travelers must stay in SHA Plus hotel at least 1 day while waiting for theresult Who? ·

Invitation to presentation of First Camp Group's report for the third quarter of 2021

First Camp Group AB's report for the third quarter of 2021 will be published on Wednesday, October 27, 2021 at around 08:00.A digital conference will be held at 10:00. At the conference, Johan Söör, CEO and Göran Meijer, CFO, will present the report, followed by a question and answer session. The presentation will be held in English. A presentation and video link to the conference will be available at https://corporate.firstcamp.se/en/for-investors from the time the report for the third quarter of 2021 is published.

Invitation to presentation of First Camp Group's report for the third quarter of 2021

First Camp Group AB's report for the third quarter of 2021 will be published on Wednesday, October 27, 2021 at around 08:00.A digital conference will be held at 10:00. At the conference, Johan Söör, CEO and Göran Meijer, CFO, will present the report, followed by a question and answer session. The presentation will be held in English. A presentation and video link to the conference will be available at https://corporate.firstcamp.se/en/for-investors from the time the report for the third quarter of 2021 is published.

Oncopeptides withdraws Pepaxto®[ ]in US, scale down organization and focus on R&D

STOCKHOLM — October 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the company has decided to withdraw Pepaxto[® ](INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogue with the US Food and Drug Administration, FDA. Pepaxto was granted accelerated approval on February 26[th] 2021.

Latest innovations in RayStation, RayCare and RayIntelligence to be presented at ASTRO 2021

RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2021 , to be held in Chicago, October 24-27. Attendees will be able to book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and RayIntelligence®, the new cloud-based analytics system for oncology, during the congress.The latest versions of RayStation (11A) and RayCare (5A) were released in May 2021. A new feature in the RayStation release is dose planning for Accuray’s CyberKnife® system for

Targovax invites to webcast presentation on Xtrainvestor

Oslo, Norway, 22 October 2021 – Targovax ASA (OSE: TRVX) has the pleasure of inviting investors, analysts and media to a live webcast presentation held by the company’s newly appointed CEO Erik Digman Wiklund on Monday 25 October at 14:00 CEST.Webcast URL: https://inqrate.com/xtravideos/targovax-trvx-presentasjon-25-oktober/ The presentation will be followed by a Q&A session moderated by analyst in DNB Markets Patrik Ling. Webcast viewers are welcome to submit questions in advance or during the presentation to info@xtrainvestor.com. ***

Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET

Uppsala, Sweden – October 22, 2021 – As previously communicated Orexo will announce the Q3 2021 Interim Report, on November 3 at 8 am CET. The same day at 1 pm CET analysts, investors and media are invited to attend a presentation where Nikolaj Sørensen, CEO, Dennis Urbaniak, EVP Digital Therapeutics and Joseph DeFeo, CFO, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to ir@orexo.com, no later than 11 am CET. Please view the instructions below on how to participate. Video link: https://tv.streamfabriken.com/orexo-q3-2021

BICO has been awarded the Swedish Government’s Award Exporter of the Year 2021

BICO has today been awarded the Swedish Government’s Award, Exporter of the Year 2021. The Award was presented by the Minister for Foreign Trade Anna Hallberg at a ceremony at the Ministry for Foreign Affairs in Stockholm with the attendance of HRH Prince Daniel. The novel Award is initiated by the Swedish government in effort to promote Swedish exports, by honoring companies that have made particularly meritorious efforts in inspiration and development. The motivation from the Government reads as follows: "BICO Group is a Swedish success story whose products are designed for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top